Pharmacyclics
Poonam Jethanandani serves as the Director of Regulatory CMC at Pharmacyclics, an AbbVie Company, since August 2013, bringing extensive experience in regulatory affairs spanning over two decades. Prior roles include Associate in Regulatory Affairs at Vical, Regulatory Analyst at Pfizer, and Senior Associate in Regulatory Affairs at BioMarin Pharmaceutical, where responsibilities included leading regulatory strategies for Aldurazyme®, a treatment for Mucopolysaccharidosis. Earlier technical expertise was developed at Bio-Rad Laboratories as a Senior Technical Support Consultant, with a focus on the BioPlex® Immunoassay system. Poonam's research background includes positions as a Postdoctoral Fellow at UCSF and Northwestern University, focusing on gene regulation, reinforced by a PhD in Life Sciences from the All India Institute of Medical Sciences and an Advanced Certificate in Regulatory Affairs from San Diego State University.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.